Efficacy of HIV Post-Test Support for ANC in South Africa (SAHAPS)

This study has been completed.
Sponsor:
Collaborators:
University of KwaZulu
Information provided by (Responsible Party):
Suzanne Maman, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01683461
First received: September 7, 2012
Last updated: September 10, 2012
Last verified: September 2012
  Purpose

This is a randomized controlled intervention trial with 1,500 pregnant and postpartum women to examine the efficacy of an enhanced model of ongoing post-test support for women attending antenatal and postnatal care in KwaZulu-Natal, South Africa. Through the intervention, the investigators will tailor voluntary counseling and testing (VCT) for HIV to the ANC setting and provide a continuum of psychosocial support for pregnant women through: (1) a standardized health education video before HIV pre-test counseling; (2) HIV pre- and post-test counseling sessions that prepare women for decisions related to testing, serostatus disclosure and anti-retroviral (ARV) prophylaxis and help women plan strategies for sexual risk behavior change; (3) two additional post-test counseling sessions postpartum focusing on legal education and referral, partner testing, sexual risk behavior change and family planning decisions and; (4) an active referral system to post-test support groups run by a clinically trained staff psychologist and (5) an active referral system to legal services run by a lawyer at the clinic.

Through this intervention trial the investigators will be testing the following hypotheses:

H1: Women receiving the intervention will have significantly lower sexual risk of HIV at 14 weeks and 9-months post-partum as compared to women in the control arm. Sexual risk of HIV will be measured by: STI incidence (Trichomonas vaginalis, Neisseria gonorrhea and Chlamydia), consistent condom use, unprotected sex in past 30 days, and unprotected sex since delivery.

H2: Women receiving the intervention will report significantly better outcomes related to prevention of mother to child transmission (PMTCT) service uptake at 14 weeks and 9 months post-partum as compared to women in the control arm. PMTCT service uptake will be measured by acceptance of HIV VCT among HIV-positive and HIV-negative women; acceptance of ARVs, adherence to national infant feeding guidelines, and family planning use among HIV-positive women.

H3: Women in the intervention arm will report significantly better psychosocial outcomes at 14 weeks and 9 months post-partum as compared to women in the control arm. Psychosocial outcomes will be measured by: perceived social support, emotional distress, and partner violence among HIV-positive and HIV-negative women.


Condition Intervention
HIV
Acquired Immunodeficiency Syndrome
Behavioral: Enhanced Counseling
Behavioral: Standard of Care

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Efficacy of HIV Posttest Support for ANC in South Africa

Resource links provided by NLM:


Further study details as provided by University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • Incidence of sexually transmitted disease [ Time Frame: 14 weeks post-partum ] [ Designated as safety issue: No ]
    The investigators are using biologic markers of three STIs (Trichomonas vaginalis, Neisseria gonorrhea and Chlamydia). All women are tested for STIs at baseline and 14-weeks post-partum.


Secondary Outcome Measures:
  • Condom use [ Time Frame: 14 weeks and 9 months post-partum ] [ Designated as safety issue: No ]
    The investigators are measuring consistent condom use, unprotected sex in the past 30 days, unprotected sex since delivery (at 9 months post-partum)


Enrollment: 1500
Study Start Date: May 2008
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Enhanced Counseling
Women in the intervention arm receive: (1) a standardized health education video before HIV pre-test counseling; (2) HIV pre- and post-test counseling sessions that prepare women for decisions related to testing, serostatus disclosure and anti-retroviral (ARV) prophylaxis and help women plan strategies for sexual risk behavior change; (3) two additional post-test counseling sessions postpartum focused on legal education and referral, partner testing, sexual risk behavior change and family planning decisions and; (4) an active referral system to post-test support groups run by a clinically trained staff psychologist and (5) an active referral system to legal services run by a lawyer at the clinic.
Behavioral: Enhanced Counseling
Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
Active Comparator: Standard of Care
Women in the control arm receive the standard of care in terms of HIV counseling and testing during pregnancy. The standard of care for HIV counseling adheres to guidelines provided by the US Centers for Disease Control and the World Health Organization. Women receive one individual pre-test counseling session immediately before they are tested for HIV, and one individual post-test counseling session the same day that they are tested.
Behavioral: Standard of Care
Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Eligible women:

  1. are at least 18 years old,
  2. are not pregnant,
  3. have never tested for HIV or had most recently tested negative for HIV at least 3 months prior to recruitment,
  4. report having a primary partner who they have been with for at least 6 months,
  5. plan to live in Durban for at least the next year,
  6. plan to take their infant to the clinic for immunization visits,
  7. are able to communicate in English or Zulu, and
  8. do not need critical care for a high risk pregnancy that clinic staff is unable to provide.

Exclusion Criteria: Women are ineligible if they:

  1. are younger than 18 years;
  2. are not pregnant;
  3. have previously tested positive for HIV;
  4. do not have a primary partner defined as someone they have been with for at least 6 months;
  5. are not planning to reside in Durban for the next one year;
  6. are unable to communicate in English or Zulu;
  7. require care for high risk pregnancy that can not be provided by the clinic staff.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01683461

Locations
South Africa
University of KwaZulu-Natal
Durban, South Africa
Sponsors and Collaborators
University of North Carolina, Chapel Hill
University of KwaZulu
Investigators
Principal Investigator: Suzanne Maman, PhD University of North Carolina, Chapel Hill
Principal Investigator: Dhayendre Moodley, MMedSc, PhD University of KwaZulu
  More Information

No publications provided

Responsible Party: Suzanne Maman, Associate Professor, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT01683461     History of Changes
Other Study ID Numbers: 07-1070, R01HD050134
Study First Received: September 7, 2012
Last Updated: September 10, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of North Carolina, Chapel Hill:
HIV
AIDS

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on April 22, 2014